SCYNEXIS, Inc.

Developing Promising Novel Anti-Infectives

Our Mission

We are committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies.

We believe that our lead compound, Ibrexafungerp (formerly SCY-078), has the potential to be an essential therapy in the treatment of multiple serious fungal infections, including vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.

Team

Diversity
Integrity
Collaboration

  • Our differences make us stronger and our flexibility allows us to quickly adjust to opportunities
  • We uphold the highest scientific and professional standards
  • We foster honest and respectful teamwork

Patients

Empathy
Caring
Dedication

  • Our passion for the patient is the core foundation of our company
  • Our goal is to protect the health, safety and privacy of patients
  • We do not waiver in our support to patients, their families and their healthcare providers

Products

Innovation
Knowledge
Ingenuity

  • We aim to deliver transformational therapies
  • We pride ourselves on deep knowledge and expertise
  • We use our resourceful mindset to drive our efficiency

“Fungal species are becoming increasingly resistant to available therapies, creating an urgent global need for novel antifungal agents. We are committed to providing viable treatment options to patients struggling with serious fungal infections as quickly as possible.”

- Marco Taglietti, M.D.
President and Chief Executive Officer of SCYNEXIS